Effects of Combined Therapy with Silymarin and Glucantime on Leishmaniasis Induced by Leishmania major in BALB/c Mice

Abstract

Leishmania major is resistant to the traditional treatments in many parts of the world. PgpA, a member of (ABC) transporter superfamily, has been identified in Leishmania involved in antimony resistance. Silymarin can inhibit PgpA. The aim of this study was to determine the effect of combined therapy with glucantime and silymarin on Cutaneous Leishmaniasis. The effects of silymarin on response of L. major to glucantime were evaluated with amastigote macrophage and mice model of leishmaniasis. Immediately after injection in mice inoculated into footpads with L. major amastigote, systemic treatment was performed and the size of footpad swelling was measured twice a week. 4 and 8 weeks after the beginning of the treatment, splenic parasite burden was done. Silymarin showed no significant effect on the response of L. major promastigotes to glucantime. 2 formulations (glucantime 25 µm with silymarin 25 µm or 12.5 µm) reduced cell death in amastigote assays. The effect of silymarin on footpad swelling was detected when the combination of low-dose glucantime (20 mg/kg) with 25–50 mg/kg silymarin (especially 50 mg/kg) were used at day 22 of post infection (P<0.05). According to the parasite burden data, use of silymarin in the presence of different doses of glucantime, did not show significant effect compared to glucantime alone. The results of this study suggest that silymarin in conjunction with glucantime may have benefit effects in murine model of cutaneous leishmaniasis.

Key words

leishmania - silymarin - glucantime - phosphorylated glycoprotein A

• References

• 1 Organization WH . Scientific working group on leishmaniasis. Meeting report. World Health Publication; Geneva, Switzerland: 2004
• 2 Menon JN, Bretscher PA. Parasite dose determines the Th1/Th2 nature of the response to Leishmania major independently of infection route and strain of host or parasite. Eur J Immunol 1998; 28: 4020-4028
• 3 Minodier P, Parola P. Cutaneous leishmaniasis treatment. Travel Med Infect Dis 2007; 5: 150-158
• 4 Croft SL. Monitoring drug resistance in leishmaniasis. Trop Med Int Health 2001; 6: 899-905
• 5 Croft SL, Yardley V. Chemotherapy of leishmaniasis. Current pharmaceutical design 2002; 8: 319-342
• 6 Markle WH, Makhoul K. Cutaneous leishmaniasis: recognition and treatment. Am Fam physician 2004; 69: 1455-1460
• 7 Torres DC, Ribeiro-Alves M, Romero GA et al. Assessment of drug resistance related genes as candidate markers for treatment outcome prediction of cutaneous leishmaniasis in Brazil. Acta Trop 2013; 126: 132-141
• 8 Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol 2006; 19: 111-126
• 9 Leprohon P, Légaré D, Girard I et al. Modulation of Leishmania ABC protein gene expression through life stages and among drug-resistant parasites. Eukaryot Cell 2006; 5: 1713-1725
• 10 Pérez-Victoria JM, Pérez-Victoria FJ, Conseil G et al. High-Affinity Binding of Silybin Derivatives to the Nucleotide-Binding Domain of a Leishmania tropicaP-Glycoprotein-Like Transporter and Chemosensitization of a Multidrug-Resistant Parasite to Daunomycin. Antimicrob Agents Chemother 2001; 45: 439-446
• 11 Wei F, Liu S-K, Liu X-Y et al. Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B. Eur J Clin Microbiol Infect Dis 2013; 32: 657-669
• 12 Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 2003; 304: 1258-1267
• 13 Scambia G, De Vincenzo R, Ranelletti P et al. Antiproliferative effect of silybin on gynaecological malignancies: Synergism with cisplatin and doxorubicin. Eur J Cancer 1996; 32A: 877-882
• 14 Chiquero MJ, Pérez-Victoria JM, O’Valle F et al. Altered drug membrane permeability in a multidrug-resistant Leishmania tropica line. Biochem pharmacol 1998; 55: 131-139
• 15 Chow L, Wong AK, Ullman B et al. Cloning and functional analysis of an extrachromosomally amplified multidrug resistance-like gene inLeishmania enriettii. Mol Biochem Parasitol 1993; 60: 195-208
• 16 Henderson D, Sifri C, Rodgers M et al. Multidrug resistance in Leishmania donovani is conferred by amplification of a gene homologous to the mammalian mdr1 gene. Mol Cell Biol 1992; 12: 2855-2865
• 17 Jaafari MR, Bavarsad N, Bazzaz BSF et al. Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice. Antimicrob Agents Chemother 2009; 53: 2259-2265
• 18 Mikus J, Steverding D. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue^® . Parasitol Int 2000; 48: 265-269
• 19 Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 2000; 13: 243-248
• 20 Firouzmand H, Badiee A, Khamesipour A et al. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA). Acta Trop 2013; In press
• 21 Jaafari MR, Ghafarian A, Farrokh-Gisour A et al. Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine 2006; 24: 5708-5717
• 22 Titus R, Marchand M, Boon T et al. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 1985; 7: 545-555
• 23 Emami SA, Rabe SZT, Ahi A et al. Inhibitory Activity of Eleven Artemisia Species from Iran against Leishmania Major Parasites. Iran J Basic Med Sci 2012; 15: 807
• 24 Karimi G, Vahabzadeh M, Lari P et al. “Silymarin”, a Promising Pharmacological Agent for Treatment of Diseases. Iranian journal of basic medical sciences 2011; 14: 308-317
• 25 Kaur J, Dey CS. Putative P-Glycoprotein Expression in Arsenite-Resistant Leishmania donovani Down-Regulated by Verapamil. Biochem Biophys Res Commun 2000; 271: 615-619
• 26 Gazak R, Walterova D, Kren V. Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem 2007; 14: 315-338
• 27 Ephros M, Bitnun A, Shaked P et al. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob Agents Chemother 1999; 43: 278-282
• 28 Ashutosh Sundar S, Goyal N. Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 2007; 56: 143-153
• 29 El Fadili K, Messier N, Leprohon P et al. Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob Agents Chemother 2005; 49: 1988-1993